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Abstract

Objective To evaluate biomarkers of renal tubulointerstitial
damage and function in type 1 diabetes with and without
diabetic kidney disease.
Research design and methods Cross-sectional casecontrol study of Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications
Study participants. Cases (N=43) had incident persistent
estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2 with urinary albumin excretion >300 mg/24
hour. Controls (N=43) had persistent eGFR >90 mL/
min/1.73 m2 and urinary albumin excretion <30 mg/24
hour. Urinary and plasma biomarkers reflecting tubular
injury, inflammation, fibrosis, secretion, and synthetic
function were measured from stored specimens collected
at the first study visit with reduced eGFR (for case
participants) or the corresponding study year (for control
participants).
Results Mean (SD) age was 51 (9) and 50 (8) years for
case and control participants, and mean (SD) duration of
diabetes was 30 (6) and 30 (5) years, respectively. Mean
(SD) eGFR was 39 (14) and 103 (9) mL/min/1.73 m2 for
case and control participants, and mean (SD) albumin
excretion rate was 1978 (2914) and 10 (7) mg/day,
respectively. Comparing cases with controls, significant
differences were observed in each measured biomarker,
including urine epidermal growth factor (mean 5.3 vs
21.2 μg/g creatinine for case vs control participants,
respectively), urine monocyte chemoattractant protein-1
(596 vs 123 ng/g creatinine), urine galectin-3 (168 vs 52
μg/g creatinine), plasma soluble tubular necrosis factor
receptor-1 (3695 vs 1022 pg/mL), plasma galectin-3 (21.3
vs 11.0 ng/mL), urinary clearances of hippurate (70 vs 167
mL/min) and cinnamoylglycine (77 vs 317 mL/min), and
plasma arginine-citrulline ratio (5.6 vs 7.7 μg/μg), each
P<0.001.
Conclusions Marked abnormalities in biomarkers of
kidney tubular injury, inflammation, fibrosis, secretion,
and synthetic function accompany reduced eGFR and
albuminuria in type 1 diabetes.
Trial registration number NCT00360893, NCT00360815.

Introduction
Elevated urine albumin excretion (albuminuria) and reduced estimated glomerular
filtration rate (eGFR) have long been viewed as

Significance of this study
What is already known about this subject?
Kidney disease is a common complication of
types 1 and 2 diabetes. Diabetic kidney disease
is usually assessed using estimated glomerular
filtration rate (eGFR) and urine albumin excretion,
which predominantly reflect damage to the kidney
glomerulus.

What are the new findings?
Compared with people with type 1 diabetes and normal
eGFR and urine albumin excretion, those with abnormal
eGFR and urine albumin excretion had significant
concomitant abnormalities in urine and plasma
biomarkers that reflect damage and impaired function
of the tubulointerstitital compartment of the kidney.
The results suggest that tubular injury, inflammation,
and fibrosis as well as impairments in kidney tubule
secretion and synthesis of small molecules are
prominent features of diabetic kidney disease.

How might these results change the focus of
research or clinical practice?
This study suggests that diverse aspects of
tubulointerstitial damage and function should be
evaluated in future studies of diabetic kidney disease
and provides new information on specific biomarkers
that might be useful for this work. Ultimately, such
studies may better define the pathophysiology of
diabetic kidney disease, help develop new biomarkers
to add to eGFR and urine albumin excretion in clinical
care, and guide the development of new treatments for
diabetic kidney disease.

the cardinal manifestations of diabetic kidney
disease (DKD). These DKD manifestations
are common in type 1 diabetes, can progress
to end-stage renal disease, and are strongly
associated with cardiovascular diseases and
other adverse health outcomes.1 However,
kidney functions beyond glomerular filtration and conservation of circulating proteins
are also critical for maintaining homeostasis
and health. In particular, renal tubular cells
secrete small molecules and synthesize growth
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factors, hormones, and amino acids. Renal tubulointerestitial damage—not glomerular disease—is most strongly
associated with progression of chronic kidney disease.2,3
Further understanding of tubular damage, secretion,
and synthesis may lead to better understanding of kidney
injury in DKD, the relationship of kidney disease to other
diabetes complications, and new therapeutic targets.
Research design and methods
We performed a cross-sectional case-control study nested
within the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. The goal of the study was
to identify candidate biomarkers of tubulointerstitial
damage and function that are markedly abnormal in
DKD in order to prioritize promising biomarkers for
additional longitudinal studies.
We studied all participants with incident persistent eGFR
<60 mL/min/1.73 m2 (on two consecutive study visits),
urinary albumin excretion rate (AER) >300 mg/24 hour,
and available biosamples (N=43). Controls (N=43) were
randomly selected from DCCT/EDIC Study participants
who maintained persistent eGFR >90 mL/min/1.73 m2
and AER <30 mg/24 hour through the study visit on
which the corresponding case participant developed incident eGFR <60 mL/min/1.73 m2. Control participants
were matched to cases on duration of diabetes and DCCT
cohort (primary vs secondary intervention).
Using stored urine and plasma specimens collected
at the time of incident persistent eGFR <60 mL/
min/1.73 m2 (for cases) or at the same study year (for
controls), we measured biomarkers reflecting tubular
injury, inflammation, fibrosis, secretion, and synthetic
function. These included urine epidermal growth factor
(EGF), urine monocyte chemoattractant protein-1
(MCP-1), plasma soluble tubular necrosis factor
receptor-1 (sTNFR-1), urine and plasma galectin-3, the
urinary clearances of hippurate and cinnamoylglycine,
and plasma arginine-citrulline ratio. These biomarkers
were chosen to represent diverse aspects of tubulointerstitial damage and function that are not captured well by
eGFR and albuminuria, prioritizing those most likely to
be feasible and useful based on published literature.4-9
Aliquots of plasma and urine were collected concurrently using standardized procedures and stored at
<−70°C. For 66 participants (with samples collected
prior to August 2012), urine aliquots were taken from
4-hour collections. For 20 participants (with samples
collected after August 2012), urine was taken from a
random morning sample, based on a change in the
EDIC Study protocol. Urine EGF, MCP-1, and sTNFR-1
were measured using ELISA assays from R&D Systems.
Urine and plasma galectin-3 were measured using
ELISA assays from BGMedicine. Plasma and urine
hippurate and cinnamoylglycine and plasma arginine
and citrulline were measured by mass spectrometry.8,10
Urinary EGF, MCP-1, and sTNFR-1 were standardized to urine creatinine concentration. The urinary
2

clearances of hippurate and cinnamoylglycine were
calculated within the subset of 66 participants with
timed urine collections as urinary excretion rate
divided by plasma concentration. Differences in
biomarkers were tested using the paired T-test, based
on the case-control design.
Results
Mean age was 50.5 years and mean duration of diabetes
was 30.1 years at the time of biospecimen collection.
Case and control participants were similar with regard
to characteristics used for matching (DCCT cohort
and duration of diabetes) as well as age and gender
(table 1). Mean (SD) eGFR was 39 (14) and 103 (9) mL/
min/1.73 m2 for case and control participants, and mean
(SD) albumin excretion rate was 1978 (2914) and 10 (7)
mg/day, respectively. Blood pressure and hemoglobin
A1c (HbA1c) (particularly time-weighted HbA1c) were
higher comparing case with control participants.
The distributions of each measured biomarker differed
significantly comparing cases with controls (table 2). The
urinary excretion of EGF was markedly lower in case
versus control participants, while the urinary excretion
of MCP-1 and galectin-3 were markedly higher. Plasma
sTNFR-1 and galectin-3 concentrations were markedly
higher in case versus control participants, while plasma
arginine-citrulline ratio (a marker of tubular synthetic
function) was lower. The urinary clearances of hippurate and cinnamoylglycine were significantly lower in
case versus control participants. For urinary biomarkers,
results were similar among subsets of participants with
timed compared with random urine samples.
Discussion
We observed marked abnormalities in biomarkers of
tubulointerstitial damage and function comparing
participants with type 1 diabetes, incident eGFR <60 mL/
min/1.73 m2, and AER >300 mg/24 hour to those without
evidence of kidney disease. Differences in all eight candidate biomarkers were large and statistically significant,
despite the modest sample size. The eight biomarkers
represent diverse aspects of tubulointerstitial damage
and function, including tubular injury, inflammation,
fibrosis, secretion, and synthetic function. Our results
demonstrate that DKD in type 1 diabetes is characterized
by a broad range of abnormalities beyond reduced eGFR
and albuminuria, and suggest that diverse facets of tubulointerstitial damage and function should be evaluated in
future studies.
Tubular damage, inflammation, and tubulointerstitial
fibrosis are acknowledged mechanisms of DKD.2,6,11-13
Therefore, the observation that markers of these
processes are abnormal among patients with established
DKD is not surprising. However, the large differences we
observed reinforce the concept that tubulointerstitial
damage is a critical feature of DKD. Moreover, markers
of tubular injury, inflammation, fibrosis, secretion, and
BMJ Open Diab Res Care 2017;5:e000461. doi:10.1136/bmjdrc-2017-000461
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Table 1 Clinical characteristics of included DCCT/EDIC
Study participants with and without kidney disease
Kidney disease
status*

Table 2 Biomarkers of tubulointerstitial damage and
function among included DCCT/EDIC Study participants
with and without kidney disease
Kidney disease status*

Controls Cases
(N=43)
(N=43)
Clinical characteristics
Demographic data
 Age (years)

50 (8)

Controls
(N=43)

Cases
(N=43)

P value for
difference

Urine biomarkers†
 EGF (μg/g)

21.2 (8.7)

5.3 (2.8)

<0.0001

51 (9)

 MCP-1 (ng/g)

123 (100)

596 (860)

<0.0001

52 (35)

168 (145)

<0.0001

 Duration of diabetes (years)

30 (5)

30 (6)

 Galectin-3 (μg/g)

 Female gender

20 (47)

17 (40)

Plasma biomarkers

 DCCT intensive therapy

21 (49)

14 (33)

 sTNFR-1 (pg/mL)

1022 (256) 3695 (1289) <0.0001

 DCCT primary cohort

22 (51)

22 (51)

 Galectin-3 (ng/mL)

11.0 (5.3)

21.3 (6.6)

<0.0001

7.7 (2.8)

5.6 (1.9)

0.0004

167 (72)
317 (150)

70 (79)
77 (71)

<0.0001
<0.0001

Physical examination data
 Body mass index (kg/m )

29.3 (5.2)

30.4 (6.0)

 Arginine-citrulline
ratio (μg/μg)

 Systolic BP (mmHg)

122 (14)

137 (21)

Urinary clearance‡

 Diastolic BP (mmHg)

75 (9)

76 (13)

103 (9)

39 (14)

 Albumin excretion rate (mg/day)

10 (7)

1978 (2914)

 Current HbA1c (%)

8.0 (1.0)

8.6 (1.7)

 DCCT/EDIC time-weighted
HbA1c (%)

7.9 (0.6)

9.2 (1.1)

 EDIC time-weighted HbA1c (%)

7.9 (0.7)

9.1 (1.3)

 LDL cholesterol (mg/dL)

95 (29)

105 (39)

 HDL cholesterol (mg/dL)
 Triglycerides (mg/dL)

60 (19)
77 (35)

52 (18)
131 (73)

2

Laboratory data
 eGFR (mL/min/1.73 m2)

Cell contents are mean (SD) or N (%).
*Cases were defined by incident persistent eGFR <60 mL/
min/1.73 m2 with urinary AER >300 mg/24 hour; control subjects
were randomly selected from the pool of DCCT/EDIC Study
participants who maintained persistent eGFR >90 mL/min/1.73
m2 and AER <30 mg/24 hour through the study visit on which the
corresponding case participant developed incident eGFR <60 mL/
min/1.73 m2 and were additionally matched to cases on duration
of diabetes and DCCT cohort.
AER, albumin excretion rate; BP, blood pressure; DCCT/EDIC,
Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications; eGFR, estimated
glomerular filtration rate; HDL, high-density lipoprotein; HbA1c,
hemoglobin A1c; LDL. low-density lipoprotein.

synthetic function are not currently used in clinical care
and may ultimately be useful adjuncts to eGFR and albuminuria. Our data identify promising biomarkers to
evaluate in future longitudinal studies that evaluate this
possibility.
Recently, in a diverse population of people with chronic
kidney disease (most without diabetes), an agnostic analysis starting with transcriptomics of kidney biopsy tissue
ultimately identified reduced urinary EGF as a strong
predictor of progressive kidney disease.4 EGF is a growth
factor produced by distal tubular cells that promotes
tubular cell repair and regeneration. Membrane-bound
TNFR-1 is involved in apoptosis, survival, and key aspects
BMJ Open Diab Res Care 2017;5:e000461. doi:10.1136/bmjdrc-2017-000461

 Hippurate (mL/min)
 Cinnamoylglycine
(mL/min)

Cell contents are mean (SD).
*Cases were defined by incident persistent eGFR <60 mL/
min/1.73 m2 with urinary AER >300 mg/24 hour; control subjects
were randomly selected from the pool of DCCT/EDIC Study
participants who maintained persistent eGFR >90 mL/min/1.73
m2 and AER <30 mg/24 hour through the study visit on which the
corresponding case participant developed incident eGFR <60 mL/
min/1.73 m2 and were additionally matched to cases on duration
of diabetes and DCCT cohort.
†Urinary biomarkers are expressed per gram of urine creatinine.
‡Urinary clearances are restricted to 66 participants with timed
urine collections.
AER, albumin excretion rate; DCCT/EDIC, Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and
Complications; eGFR, estimated glomerular filtration rate; MCP-1,
monocyte chemoattractant protein-1; sTNFR-1, plasma soluble
tubular necrosis factor receptor-1.

of inflammation and immune response. The soluble form,
sTNFR-1, was previously associated with rapid kidney function decline and incident eGFR <60 mL/min/1.73 m2 in the
Joslin study of type 1 diabetes.5 Urine MCP-1, a more specific
marker of renal inflammation, was associated with eGFR
loss in type 2 diabetes.6 Plasma concentration of GDF-15, a
member of the TGF-β cytokine superfamily, correlated with
GDF-15 expression in renal tubular cells and was associated
with progression of kidney disease in populations with established chronic kidney disease (with and without diabetes).7
Tubular functions, including secretion and synthetic
function, have been less comprehensively studied in DKD.
Many proposed uremic toxins are small organic molecules
that circulate bound to plasma proteins, such as albumin,
and are poorly filtered but actively secreted by proximal
tubular cells. Hippurate and cinnamoylglycine are examples of such small molecules, which accumulate with kidney
disease in a manner that is not necessarily proportional to
reduction in GFR.8 Renal tubular cells also perform many
synthetic functions, such as the production of arginine from
citrulline.9 Additional renal synthetic functions include
3
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production of hydroxylated vitamin D metabolites, gluconeogenesis, ammoniagenesis, and erythropoietin production. Accumulation of uremic solutes and reduced synthesis
of important nutrients and hormones may promote insulin
resistance, atherosclerosis, and other pathologic processes
contributing to adverse health outcomes of chronic kidney
disease.8,14,15 Our results suggest that biomarkers of tubulointerstitial damage and function previously examined in
other populations and evaluated in this study may be useful
in type 1 diabetes.
The main limitation of our study is the cross-sectional
design, from which we cannot determine the sequence of
change in renal biomarkers or the utility of tubulointerstitial biomarkers for predicting kidney disease progression or
other complications. Compared with control participants,
those with DKD had higher systolic blood pressure and
a history of worse glycemic control, but we cannot determine the extent to which hyperglycemia and hypertension
contributed to tubulointerstitial damage and impaired
tubular function. We are unable to discern whether urine
biomarkers arise from the tubulointerstitial compartment
of the kidney or appear in the urine through filtration.
In addition, our candidate biomarker approach necessarily excludes some potentially important biomarkers.
Study strengths include the simultaneous evaluation of
biomarkers reflecting multiple aspects of tubulointersititial
damage and function, the well-characterized cohort with
robust control subjects, the use of novel and precise mass
spectrometry assays for some analytes, and the strength of
the observed associations.
Conclusion
In type 1 diabetes, marked abnormalities in biomarkers
of kidney tubular injury, inflammation, fibrosis, secretion,
and synthetic function accompany reduced eGFR and albuminuria. Longitudinal studies are needed to determine the
time course over which these biomarkers of tubulointerstitial function change relative to eGFR and albuminuria and
to determine whether these biomarkers are associated with
DKD progression and complications. Biomarkers of tubulointerstitial damage and function may be useful for the
development of new therapies targeting DKD.
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